Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is gingerbread, for those tracking this sort of thing. And remember that no prescription is required. So no need to calculate rebates. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch. …
Over four decades, GSK chose to keep quiet on the cancer risks of the recalled heartburn medication Zantac, Bloomberg BusinessWeek reports. The U.S. Food and Drug Administration considered the cancer risks when approving the drug, but the company did not share a critical study. Over the years, GSK also backed flawed research designed to minimize concerns and chose not to routinely transport and store the medication in ways that could have eased the problem. The drug was pulled from the U.S. market in 2020 amid concerns over the unacceptable levels of a potential human carcinogen known as NDMA.
The Biden administration announced three new drug-pricing policy experiments that would standardize how much Medicare patients pay for certain generic drugs, pilot new ways for Medicaid to pay for pricey cell and gene therapies, and test ways to pay for drugs approved without proven clinical benefit, STAT says. The proposals follow an executive order President Biden signed last year directing the administration to develop demonstrations to complement a new drug-pricing law. The U.S. Centers for Medicare and Medicaid Services uses demonstrations to pilot test policy ideas, and if those policies work out, the agency can expand them into programs without the approval of Congress.
Create a display name to comment
This name will appear with your comment